Julie Waras Brogren

Director of the Board

Julie Waras Brogren (Danish, born 1972) joined  Pila Pharma in 2024 as Director of the Board due to her extensive experience in developing strategies for advancing pharma assets from development to commercialization and in finance and investor relations.

Julie Waras Brogren holds a M.Sc. in International Business Administration (2001) from Copenhagen Business School and a M.Sc./Diplôme ESC from Ecole de Management de Lyon, France (2000).

She has over 20 years of life science experience from leadership positions in pharma and medical device companies and has served as Board member and Board Chair in early-stage life science companies.

Julie Waras Brogren is currently Deputy CEO of Ascelia Pharma AB (publ: ACE) (2013-2015) with responsibility for the duties of the Chief Financial Officer, including Investor Relations, and Chief Commercial Officer, including Business Development. She joined Ascelia Pharma in 2020 and has been part of several financing rounds. At Ascelia Pharma, she has developed corporate, product and launch strategies for an orphan liver imaging drug, currently in phase 3 development, and a phase 2 ready gastric cancer therapy. Julie was previously President of the sleep apnea signal processing medtech, BresoTEC, in Canada and has held various leadership positions at Novo Nordisk in Corporate Finance and in Global Marketing and Latin America. While in Novo Nordisk, she developed the first global cross-functional launch office for the launches of liraglutide GLP-1 and degludec insulins. She started her career at Accenture as a consultant.

Julie has board experience from Ossiform, developing 3D printed bone implants, and Maribo Medico (acquired by ResMed).

Share ownership in the company: 5000 (direct)